Clinical Trial Update: Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating CG0070 in combination with nivolumab in cisplatin-ineligible muscle-invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• CG0070
• Opdivo (nivolumab) (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Phase 1 | Status: COMPLETED